Chief Executive Officer, Adaptimmune Therapeutics plc
Adrian Rawcliffe serves as the Chief Executive Officer and on the board of directors at Adaptimmune Therapeutics plc, where he also previously served as their Chief Financial Officer. He has more than 20 years of experience within the pharmaceutical and biotechnology industries and previously served as Senior Vice President, Finance of GlaxoSmithKline’s (GSK) North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture capital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, U.K.